Navigation Links
ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
Date:7/21/2014

SAN DIEGO, July 21, 2014 /PRNewswire/ -- An International Trade Commission (ITC) ruling issued Friday held that, despite a redesign of its iCH CPAP device, Taiwanese device manufacturer APEX continues to infringe ResMed patents in its humidification. ResMed (NYSE: RMD) is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

"Our research and development teams are constantly researching and improving designs to reach new levels of comfort, performance and efficacy," said David Pendarvis, ResMed chief administrative officer and global general counsel. "This result – and APEX's own expert – affirms that the superior quality and functionality generated by ResMed innovation cannot be duplicated."

The original ITC action filed by ResMed in March 2013 asserted patent infringement by four products: APEX iCH and XT Fit CPAP humidifiers, the WiZARD 220 full face mask, and the WiZARD 210 nasal mask.
In July 2013, APEX agreed to entry of an order prohibiting it from infringing ResMed's patents.  And as a result, APEX has been banned from selling infringing products in the United States. 

APEX then redesigned its products and sought a ruling that it had avoided ResMed's patents. In this new ruling, the full commission held that the APEX iCH humidifier continues to infringe.  As a result, APEX should continue to be banned from selling the iCH humidifier in the United States. The redesigned APEX XT Fit was found not to infringe. But APEX's own expert stated that the redesigned humidifiers compromised on functionality and performance.  The redesigned WiZARD 220 full face mask – which now has a fused elbow instead of the more desirable detachable elbow -- was found not to infringe on ResMed patents.  Again, APEX's expert noted that the redesigned masks sacrificed functional advantages present in the ResMed products.  Finally, APEX chose to withdraw its redesigned WiZARD 210 nasal mask from these proceedings, so the July 2013 order remains in place as to that product.

About ResMed:
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts: For News Media For InvestorsGretchen Griswold

Agnes LeeDirector, Global Corporate Communications

Senior Director, Investor RelationsO: 858-836-6789

O: 858-836-5971news@resmed.com

investorrelations@resmed.comLogo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a


'/>"/>
SOURCE ResMed Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
2. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
3. Announcement Under Irish Takeover Rules Relevant Securities in Issue
4. 2013 Chinese Pharmaceutical Guidebook: Drug Registration Rules
5. Arizona Judge Rules That Arizona Medical Marijuana Law is Constitutional
6. EMD Seronos Redesigned Fertility Pen Available for Distribution in US
7. Upsher-Smith Introduces Newly Redesigned Corporate Website
8. Vicks Starry Night Humidifier Available Now in New Colors Exclusively at Babies"R"Us
9. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
10. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
11. Yaz Settlement Funding News: 10K Cases Still Not Settled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):